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A B S T R A C T
The aim of this study is to evaluate the effect of moderate physical exercise and treat-
ment time on the organism’s response to NSC631570.The sensitivity of circulating phagocytes
to the drug at different times of day was estimated in in vitro experiments. NSC631570 was
administered intravenously to healthy volunteers (eleven men, 23 ± 2 years) in a single thera-
peutic dose in an inpatient and an outpatient setting. Blood samples were obtained before
the drug administration, 30 min after the drug injection and every fourth hour throughout
the 24 hour period. Biochemical parameters were determined using the hematological ana-
lyzer. Flow cytometry was used to evaluate phagocyte metabolism. Treatment of circulating
phagocytes with NSC631570 in vitro resulted in an increase in ROS production along with a
decrease in their phagocytic activity, most expressed in the morning time. Drug injection
to sedentary persons resulted in pro-inflammatory metabolic polarization of circulating phago-
cytes. Introduction of NSC631570 to active persons was accompanied by a significant increase
in phagocyte endocytosis along with a decrease in the daily mean of ROS generation. Sig-
nificant oscillation (but in the normal ranges) of urea, creatinine, alanine aminotransferase
and aspartate aminotransferase after NSC631570 introduction in the outpatient setting was
shown during the day. Physical activity interferes with immunomodulatory action of
NSC631570 and abrogates pro-inflammatory shift of circulating phagocytes. Biochemical pa-
rameters of blood from patients treated with NSC631570 in the outpatient setting must be
interpreted cautiously considering the effect of physical activity on some metabolic biomarkers.
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1. Introduction
NSC631570 is a derivative of the extract of the plant Chelido-
nium majus L. and thiophosphoric acid [1–5]. The drug consists
of a mixture of eight C. majus alkaloids (chelidonine, sanguina-
rine, chelerythrine, protopine, allocryptopine, homochelidonie,
berberine, and coptisine) that reacted with an alkylating agent
(preferably thiotepa) in organic solvent. The preparation has
the ability to be selectively accumulated in tumor tissue and
activate apoptosis only in tumor cells and not in normal cells,
probably due to increased consumption of the drug by tumor
cells [5–8]. In addition, the therapeutic effect of NSC631570 is
always accompanied by the stimulation of immune responses.
The preparation shows an ability to modulate immunologic re-
activity in vivo and to alter functions of immunocytes including
phagocytes in vitro [9–11].
In accordance with their functions and metabolism, phago-
cytes have been classified into two subpopulations. Classically,
activated cells (M1 macrophages or N1 neutrophils) exhibit pro-
inflammatory phenotype that is characterized by increased
production of reactive oxygen species, pro-inflammatory
cytokines and chemokines. Alternatively, activated M2 mac-
rophages or N2 neutrophils are described as cells with anti-
inflammatory phenotype with increased phagocytic activity and
regulatory cytokine expression [12,13]. In our previous inves-
tigation, we observed the ability of NSC631570 to cause an influx
of macrophages into the tumor growth area after intrave-
nous administration [9].The previous result from our laboratory
also revealed that NSC631570 induces M1 functional polariza-
tion of peritoneal macrophages and circulating phagocytes in
tumor-bearing mice and can restore pro-inflammatory func-
tions of macrophages, alternatively polarized by hypoxia in vitro
[14]. Thus, the modulation of phagocyte functions can be con-
sidered as an important component of the immunomodulatory
effect of NSC631570.
The efficacy of an immunomodulating preparation depends
on the reaction of immune cells to the given drug. This reac-
tion of immune cells substantially depends on their initial
functional state [15].The initial functional state of immune cells
in turn depends on many factors that are rarely appreciated
in the treatment regimen such as treatment time and condi-
tion of the patients (inpatient vs outpatient setting). Numerous
studies have demonstrated that even moderate physical ex-
ercise modulates the functional response of immune cells,
including monocytes and granulocytes and affects cytokine gen-
eration, reactive oxygen (ROS) and nitrogen species production,
and chemotaxis and phagocytosis of these cells [16–20]. It is
widely reported that therapeutic effects can be markedly im-
proved by administering a drug taking into account the rhythm
of cell functions [21–25]. Treatment with NSC631570 is carried
out in the morning in both inpatient (associated with limited
excursion) and outpatient settings (associated with moder-
ate physical activity). Clinical observations suggest that the
therapeutic efficacy of the drug is lower when treatment is
carried out in an outpatient setting.
Traditionally, biochemical parameters have been used as
markers to assess the influence of exercise on different systems,
organs and tissues [26–28]. Many biochemical parameters also
exhibit diurnal variations that must be considered in the clinical
setting, when concentration changes in the parameters are
evaluated.
The aim of this study was to evaluate the effect of treat-
ment time and moderate physical exercise on the response of
circulating phagocytes to NSC631570 as well as on daily os-
cillations of various biochemical blood parameters after drug
administration.
2. Materials and methods
2.1. Subjects
Eleven healthy adult men aged 23 ± 2 years were recruited to
participate in the study. Exclusion criteria included a history
of somatic disease and a physically active lifestyle. Approval
was obtained from the Ethics Committee of the City Clinical
Emergency Hospital of Kyiv, and consent was obtained from
all subjects before the commencement of the study.
2.2. Study design
The studies were carried out in three stages. The aim of the
first stage was to investigate the effect of treatment time on
the sensitivity of circulating phagocytes to NSC631570 in vitro.
For this purpose, blood samples of 5 healthy volunteers in the
inpatient setting were collected at different times of day (start-
ing at 8:00 h then every 4 h over the next 24 h). Blood samples
from each point in time were immediately treated with
NSC631570 (Nowicky Pharma, Austria) at a concentration of
20 μg/ml. Phagocytic activity and ROS generation of circulat-
ing monocytes and granulocytes were analyzed in treated and
untreated samples. The aim of the second stage was to imitate
administration of the drug in the inpatient setting (inpatient
setting model). For this purpose, 11 volunteers spent most of
their time in bed. NSC631570 was administered i.v. at 8:00 h
at a volume of 20 ml (a single therapeutic dose in clinical prac-
tice). Blood samples were collected before and 30 min after drug
administration (at 8:30 h), as well as every 4 h over the next
16–24 h. The aim of the third stage was to imitate adminis-
tration of the drug in the outpatient setting (outpatient setting
model). For this purpose, 11 volunteers were allowed to move
and in addition they were asked to take part in one session
of standardized moderate physical exercise. NSC631570 was
administered i.v. at 8:00 h at a volume of 20 ml. The physical
exercise program (at 12:00 h) included 50 slow squats. Blood
samples were collected before and 30 minutes after drug ad-
ministration, before standardized moderate physical exercise,
immediately after it, and every 4 h over the next 16–24 h. Phago-
cytic activity and ROS generation of circulating monocytes and
granulocytes as well as biochemical parameters were ana-
lyzed in all collected blood samples.
2.3. Intracellular ROS assay
ROS levels were measured using 2′7′-dichlorodihydro-fluorescein
diacetate (carboxy-H2DCFDA, Invitrogen), which is converted
into a non-fluorescent derivative (carboxy-H2DCF) by intra-
cellular esterases as described earlier [29]. Carboxy-H2DCF is
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membrane impermeable and is oxidized to fluorescent de-
rivative carboxy-DCF by intracellular ROS. Two hundred
microliters of heparinized whole blood was incubated with 4.3 μl
of PBS containing 10 μM carboxy-H2DCFDA for 30 min at 37 °C.
A short recovery time was allowed for the cellular esterases
to hydrolyze the acetoxymethyl ester or acetate groups and
render the dye responsive to oxidation. Erythrocytes were lysed
with lysis buffer. The cells were then transferred to polysty-
rene tubes with cell-strainer caps (Falcon, Becton Dickinson)
and analyzed with flow cytometry (excitation: 488 nm, emis-
sion: 525 nm). Only living cells, gated according to scatter
parameters, were used for the analysis.
The modulating effect of the drug in vitro was character-
ized by the modulation coefficient that was calculated by the
formula 100 − (S − 100/B), where S is the index value after treat-
ment with NSC631570 in vitro; B is the index value of untreated
cells (basal value).
The modulating effect for in vivo experiment was repre-
sented as a percentage of daily mean value.
2.4. Phagocytosis assay
The flow cytometry phagocytosis assay was performed as de-
scribed above [29]. Staphylococcus aureus Cowan I cells (collection
of the Department of Microbiology and General Immunology
of Taras Shevchenko National University of Kyiv) were grown
on beef-extract agar and subsequently were heat inactivated
and fluorescein isothiocyanate (FITC) labeled.
The stock of FITC-labeled S. aureus at a concentration of
1 × 107 cells/ml in a volume of 5 μl was added to 200 μl of hepa-
rinized whole blood. A tube with whole blood only served as
a negative control. All samples were incubated at 37 °C for
30 min. At the end of the assay, phagocytosis was arrested by
the addition of cold stop solution (PBS with 0.02% EDTA and
0.04% paraformaldehyde). Erythrocytes were lysed with lysis
buffer. Fluorescence of phagocytes with ingested bacteria was
determined by flow cytometry. The results were registered as
phagocytosis index (PhI) that was calculated with the follow-
ing formula: [Gmeanpos/Ppos ] − [Gmeanneg/Pneg], where Ppos
is the percent of positive cells, Gmeanpos is the mean channel
fluorescence, Pneg is the percent of positive cells in the nega-
tive control, and Gmeanneg is the mean channel fluorescence
of the negative control. The modulating effect of the drug in
vitro was evaluated as mentioned above.
2.5. Evaluation of biochemical parameters
The concentrations of glucose, urea, creatinine, sodium, chlo-
ride, amylase, phosphorus, cholesterol, triglycerides, direct high-
density lipoprotein cholesterol (HDLC), uric acid, total protein,
albumin, aspartate aminotransferase (AST), alanine amino-
transferase (ALT), alkaline phosphatase (ALKP), gamma-
glutamyl transferase (GGT), and total bilirubin (TOTAL BILI) were
determined using the hematological analyzer Particle counter
model PCE 210 (ERMA, Japan).
2.6. Statistical analysis
Data are reported as mean ± SD. To perform statistical analy-
sis, daily mean values of all investigated indices were calculated
for each individual. PhI and ROS generation values were then
normalized to daily mean and used for calculation of
means ± SD. Means were compared using the Student’s t-test,
and P values of 0.05 or less were considered significant.
3. Results and discussion
3.1. The treatment time dependence of circulating
phagocytes’ sensitivity to NSC631570 in vitro
The effect of treatment time on the sensitivity of circulating
phagocytes to the antineoplastic drug NSC631570 was evalu-
ated in in vitro experiments. The functional state of phagocytes
that was characterized by increased phagocytic activity along
with decreased ROS generation was considered as anti-
inflammatory or alternative polarization. In contrast, the
functional state of phagocytes that was characterized by de-
creased phagocytic activity along with increased ROS generation
was considered as pro-inflammatory or classic polarization
[12,14,30].
Functional polarization of circulating monocytes de-
pended on the time of day (Fig. 1). Pro-inflammatory metabolic
profile in circulating monocytes at 4 pm was identified by a
72% increase (as compared with daily mean value) in ROS
generation accompanied by a 46% reduction in phagocytosis.
Anti-inflammatory polarization of these cells characterized
by a 54% increase in phagocytic activity along with a 15%
decrease in ROS production was registered at midnight. Meta-
bolic polarization of circulating phagocytes at the other time
points was absent or could be considered as a neutral func-
tional state. Treatment of blood samples with NSC631570 in
vitro at all time points resulted in an increase in ROS genera-
tion and a decrease in phagocytic activity in monocytes
indicating the pro-inflammatory modulating effect of the drug.
The most expressed pro-inflammatory effect of the drug on
metabolic polarization of circulating monocytes in treated
samples was detected at 8 h. In this time point, untreated
monocytes were characterized by a neutral functional profile.
This time point is closest to the time point of NSC631570
introduction in clinical practice.
Functional polarization of circulating granulocytes also
showed time-dependent variations over the period of obser-
vation (Fig. 2). Similarly to monocytes, a significant increase
(110% from daily mean value) in ROS production accompa-
nied by relatively low phagocytic activity was observed in
circulating granulocytes at 16:00 h indicating their classical (N1)
polarization at this time point. Moderate anti-inflammatory (N2)
polarization of these cells, characterized by the enhanced
phagocytic properties (80% from daily mean value), was reg-
istered at 20:00 h. At the other time points, circulating
granulocytes did not display distinct metabolic polarization and
their functional state was considered as neutral. Treatment of
blood samples with NSC631570 in vitro at different time points
over the day caused an increase in ROS generation in circu-
lating granulocytes, most expressed at noon. In this time point,
untreated granulocytes were characterized by a neutral meta-
bolic profile.
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3.2. Circulating phagocytes’ polarization after the
introduction of NSC631570 in inpatient and outpatient
settings
Clinical investigations revealed that the therapeutic effect of
NSC631570 is greater when treatment is provided in the in-
patient setting associated with limited physical exercise. Thus,
the second research task was to investigate the effect of mod-
erate physical exercise (that is characteristic for patients in an
outpatient setting) on the sensitivity of circulating phago-
cytes to NSC631570. Physical activity is a systemic phenomenon
with impact on immune cell function. The effect of physical
activity on immune cells depends on its intensity and regimen
as well as participant age [17,20]. Of innate immune system
cells, neutrophils and macrophages appear to be most respon-
sive to the influence of physical activity, both in terms of
numbers and function.
In vivo introduction of NSC631570 in an inpatient setting
caused pro-inflammatory polarization of circulating mono-
cytes 4 h after drug injection (Fig. 3). This functional state of
cells was registered for the following 8 h, whereas introduc-
tion of the drug in an outpatient setting was associated with
moderate anti-inflammatory polarization of monocytes, which
in this case was characterized by significantly increased
phagocytic activity (by 76% at 12:00 h) and moderate oxida-
tive metabolism. Phagocytic function of these cells showed a
further 20% increase immediately after physical exercise as de-
termined at 12:30 h. Starting from 16:00 h (4 h after the bout
of physical activity), both oxidative metabolism and
phagosytosis in circulating monocytes were significantly de-
creased. Slight features of the anti-inflammatory metabolic
profile of these cells were observed. Interestingly, phagocytic
activity of monocytes before drug introduction was slightly
higher in sedentary volunteers than that in an active state. It
is a well-known fact that moderate physical activity pro-
motes alternative polarization of mononuclear phagocytes
[8,9,18]. Acute moderate physical activity led to further alter-
native polarization of monocyte metabolism although it was
not defined as prolonged.
Intravenous administration of NSC631570 also resulted in
pro-inflammatory polarization of circulating granulocytes in
sedentary persons 30 minutes after drug introduction (Fig. 4).
These cells were characterized by significantly increased oxi-
dative metabolism (by 66% as compared with daily mean) along
with decreased phagocytic activity (by 27%). Drug injection to
active volunteers did not change their polarization. Slightly ex-
pressed features of anti-inflammatory metabolic polarization
of these cells were registered 4 h after the bout of physical
Fig. 1 – Functional polarization of circulating monocytes before and after treatment with NSC631570 in vitro. (A) Functional
polarization of circulating monocytes from healthy volunteers; (B) functional polarization of circulating monocytes from
healthy volunteers after treatment with NSC631570 in vitro. Each value represents the mean ± SD of 5 healthy volunteers.
*P < 0.05 was considered significant compared to phagocytic index value.
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exercise (at 16:00 h) and over the next 12 h.These results suggest
that physical activity interferes with the influence of NSC631570
on circulation granulocytes of healthy volunteers and abro-
gates the pro-inflammatory effect of the drug on these cells.
3.3. Patterns of biochemical parameter oscillations after
NSC631570 introduction in vivo in an inpatient and an
outpatient setting
Clear time-of-day-dependent changes have been shown to be
relevant for some biochemical parameters of the human blood.
Biochemical markers are known to oscillate in response to a
number of environmental agents and physiological activity.
Acute bouts and chronic exercises have an effect on meta-
bolic processes and might serve as the underlying reason for
significant alterations in biochemical and hematological mea-
surements [26,27].
Administration of NSC631570 in the early morning (at 8:00 h)
did not cause significant changes in levels of biochemical
markers measured in blood samples of healthy men in an in-
patient setting 30 min after injection (Table 1). All of the
biochemical markers corresponded to the normal range of
values for healthy individuals of the same age. Meanwhile, total
bilirubin concentration showed a transient increase immedi-
ately after injection followed by a fall at noon to normal (daily
mean) values determined for this parameter. It may reflect an
overlapping of the effect of the drug and the peak value of total
bilirubin that occurred in the morning as described for diurnal
variation in this biochemical marker of blood [27]. Signifi-
cantly higher concentrations than daily mean value was
registered in amylase, cholesterol, and triglycerides with peaks
for these measures at 20:00 h, 16:00 h and at noon, respec-
tively.The lowest values, that were significant as compared with
daily mean, were observed for cholesterol at noon and for high-
density lipoprotein cholesterol at midnight. We suppose that
this showed that the trend was linked to normal daily fluc-
tuation of the mentioned biochemical parameters. Moreover,
food intake might have a major effect on the extent of daily
fluctuation of such parameters as triglycerides, cholesterol and
high-density lipoprotein cholesterol, levels of which can in-
crease rapidly after a high-fat meal [31–35].
In active volunteers (Table 2), administration of NSC631570
led to a sharp increase in the concentration of gamma-
glutamyl transferase (by 67% from basal level) in 30 min after
drug introduction (at 8:30 h). Also, the comparison of daily mean
values of biochemical measures from active and sedentary
Fig. 2 – Functional polarization of circulating granulocytes before and after treatment with NSC631570 in vitro.
(A) Functional polarization of circulating granulocytes from healthy volunteers; (B) functional polarization of circulating
granulocytes from healthy volunteers after treatment with NSC631570 in vitro. Each value represents the mean ± SD of 5
healthy volunteers. *P < 0.05 was considered significant compared to phagocytic index value.
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volunteers showed significant differences in levels of glucose
(lower by 20% in outpatient setting), creatinine (higher by 11%
in outpatient setting), alanine aminotransferase (higher by 61%
in outpatient setting) and alkaline phosphatase (lower by 75%
in outpatient setting). Some of the observed alterations, in par-
ticular the increase in glucose intake and increase in creatinine
as well as alanine aminotransferase and aspartate amino-
transferase (peaked in the evening), reflect the metabolic
outcome of muscle activity and energy output [31]. This is the
main reason why taking moderate-intensity physical exer-
cise was associated with more variable biochemical parameters
in healthy active volunteers who were given NSC631570 in-
jection. In an outpatient setting, of the measured parameters,
urea, amylase, and triglycerides showed significant increases
30 min after a single bout of physical activity (at 12:30 h). Al-
though increased urea, marker of protein catabolism, reflects
the process of protein utilization as an energy substrate during
acute bouts [26], variations of amylase and triglyceride
concentrations might occur as a result of exercises on gastro-
intestinal tract (including liver) and enzyme synthesis. Also,
some changes in blood parameters and immune cells activ-
ity can be influenced by stress hormones and cytokines.
4. Conclusion
The present data show that both treatment time and moder-
ate physical activity influence the immunomodulating effect
of the antineoplastic drug NSC631570. Treatment time-
dependency of the sensitivity of circulating phagocytes to
NSC631570 was revealed.The drug caused most expressed pro-
inflammatory stimulation of these cells during the early
morning when the metabolic profile of investigated phago-
cytes can be considered as neutral. Physical activity interferes
with the immunomodulatory action of NSC631570 and abro-
gates M1 (N1) shift of circulating phagocytes. Administration
of NSC631570 in an inpatient setting did not cause any sig-
nificant alterations in blood biochemical parameters. Increased
values of urea, creatinine, alanine aminotransferase and
Fig. 3 – Functional polarization of circulating monocytes after a single injection of NSC631570 in inpatient and outpatient
settings. (A) Functional polarization of circulating monocytes in healthy volunteers after the introduction of NSC631570 in
the inpatient setting; (B) functional polarization of circulating monocytes after the introduction of NSC631570 in the
outpatient setting. Each value represents the mean ± SD of 11 healthy volunteers. *P < 0.05 was considered significant
compared to phagocytic index value.
313a s i an j o u rna l o f p h a rma c eu t i c a l s c i e n c e s 1 1 ( 2 0 1 6 ) 3 0 8 – 3 1 7
Table 1 – Blood biochemical parameters in healthy men after the single injection of NSC631570 in inpatient setting.
Parameter, Units Values
Value at the time of 8:00
BDI (SD)
Value at the time of 8:30
ADI (SD)
Daily mean value
(SD)
Peak,
clock time
Max. value over the 16 h
time period
ADI (SD)
Drop,
clock time
Min. value over the 16 h
time period
ADI (SD)
Glucose, mmol/l 5 (0.8) 5.6 (0.6) 6.3 (0.37) 16:00 7.4 (0.9) 12:00 6.4 (0.3)
Urea, mmol/l 5.8 (0.3) 5.6 (0.2) 6.32 (0.26) 16:00 7 (0.9) 12:00 5.8 (0.1)
Creatinine, mkmol/l 75 (4.4) 76 (3.1) 73 (1.2) 16:00 75 (5.1) 12:00 69 (5.9)
Sodium, mmol/l 135 (5.7) 136 (6.1) 137.2 (1.9) 0:00 144 (3.8) 12:00 130 (4.9)
Chloride, mmol/l 104 (3.7) 92 (4.1) 95.8 (2.6) 00:00 100 (5.1) 12:00 86 (7)
Amylase, U/l 30 (4.2) 30 (1.8) 32.7 (1.6) 20:00 39 (1.5)a 0:00 30 (1.1)
Phosphorus, mmol/l 1.26 (0.08) 1.2 (0.3) 1.30 (0.1) 00:00 1.69 (0.3) 12:00 1.16 (0.1)
Cholesterol, mmol/l 4.1 (0.3) 4.1 (0.4) 4.1 (0.21) 16:00 4.9 (0.2)a 12:00 3.3 (0.2)a
Triglycerides, mmol/l 0.63 (0.09) 0.65 (0.2) 0.68 (0.07) 12:00 1 (0.1)a 20:00 0.58 (0.09)
Direct HDLC, mmol/l 1.19 (0.06) 1.35 (0.2) 1.26 (0.14) 20:00 1.56 (0.06) 00:00 0.61 (0.08)a
Uric acid, mkmol/l 301 (11.4) 298 (17.9) 287.3 (4.25) 16:00 285 (15.8) 12:00 273 (13.3)
Total protein, g/l 74.9 (8.8) 71.9 (7.3) 75.1 (1.73) 20:00 80 (8.1) 12:00 68.6 (13.7)
Albumin, g/l 47 (4.3) 46 (2.9) 46.3 (0.71) 12:00 49 (2.7) 0:00 44 (4.1)
AST, U/l 16 (1.9) 13 (2.5) 14.8 (1.2) 20:00 20 (2.8) 12:00 12 (2.1)
ALT, U/l 19 (2.1) 15 (1.7) 18.2 (0.5) 0:00 21 (1.6) 16:00 16 (1.7)
ALKP, U/l 40 (9.1) 42 (8.9) 42.8 (1.8) 0:00 49 (8.8) 12:00 37 (10)
GGT, U/l 20 (3.3) 10 (3.4) 21.3 (4.2) 00:00 35 (4.1) 12:00 11 (3.6)
TOTAL BILI, mkmol/l 12 (1.1) 16 (0.9)a,b 11.2 (1.1) 12:00 11 (0.8) 16:00
00:00
9 (1.2)
9 (1.9)
a P < 0.05 was considered significant compared to corresponding daily mean value.
b P < 0.05 was considered significant compared to corresponding value at 8:00 h (before the drug injection).
BDI: before drug injection; ADI: after drug injection; HDLC: high-density lipoprotein cholesterol; AST: aspartate aminotransferase; ALT: alanine aminotransferase; ALKP: alkaline phosphatase; GGT:
gamma-glutamyl transferase; TOTAL BILI: total bilirubin.
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Table 2 – Blood biochemical parameters in healthy men after the single injection of NSC631570 in the outpatient setting.
Parameter, Units Values
Value at the time of 8:00
BDI (SD)
Value at the time of 8:30
ADI (SD)
Daily mean value
(SD)
Peak,
clock time
Max. value over the 16 h
time period
ADI (SD)
Drop,
clock time
Min. value over the 16 h
time period
ADI (SD)
)5.0(5.4)6.0(5.4l/lomm,esoculG 5.1 (0.3)c 12:00 6.7 (0.6) 20:00 4.7 (0.7)
)54.0(4.6)7.0(7.5)5.0(6.5l/lomm,aerU 12:30 8.7 (0.7)a 16:00 5.3 (0.2)
)7.4(87)7.3(78l/lomkm,eninitaerC 81.1 (1.96)c 00:00 86 (4.8) 12:30 74 (3.9)
)2.5(73100:21)9.5(54100:02)1.1(3.041)7.5(041)1.4(931l/lomm,muidoS
00:21)1.5(00100:02)62.1(1.69)4.4(69)5.5(09l/lomm,edirolhC
0:00
95 (3.9)
95 (4.9)
)7.2(4.43)2.2(03)6.3(23l/U,esalymA 12:30 47 (1.8)a 12:00
16:00
30 (1.9)
30 (2.6)
00:0)90.0(73.1)80.0(92.1)2.0(21.1l/lomm,surohpsohP 1.77 (0.1)a 16:00 1.12 (0.3)
)3.0(4.400:00)5.0(500:02)90.0(6.4)2.0(8.4)1.0(3.4l/lomm,loretselohC
Triglycerides, mmol/l 0.51 (0.08) 0.57 (0.04) 0.78 (0.09) 12:30 1.2 (0.05)a 12:00 0.63 (0.07)
Direct HDLC, mmol/l 1.56 (0.03) 1.55 (0.04) 1.62 (0.05) 16:00 1.87 (0.06)a 12:30 1.5 (0.03)
)4.6(4.282)1.7(862)3.6(072l/lomkm,dicacirU 12:30 316 (13.4) 20:00 271 (9.7)
)6.7(8.5700:21)2.01(9.4800:02)52.1(2.08)2.11(5.08)7.4(9.28l/g,nietorplatoT
)1.6(7400:21)2.3(8400:61)2.0(6.74)3.6(84)2.2(74l/g,nimublA
00:02)8.9(7.12)2(51)2(21l/U,TSA 80 (3.5)a 12:30 7 (3.6)
)7.2(23)2.2(92l/U,TLA 29.4 (2.1)c 16:00 40 (1.9)a 00:00 23 (3)
)3.2(21)9.1(01l/U,PKLA 11.1 (0.55)c 16:00 14 (1.1) 20:00 10 (0.9)
)7.2(42l/U,TGG 40 (3.1)b 29.4 (3.0) 20:00 38 (4.8) 00:00 19 (4.3)
)4.1(9100:00)2.1(6.51)1.1(51)1.1(81l/lomkm,ILIBLATOT 12:30 10 (1.9)
a P < 0.05 was considered significant compared to corresponding daily mean value.
b P < 0.05 was considered significant compared to corresponding value at 8:00 h (before drug injection).
c P < 0.05 compared with corresponding daily mean value in the inpatient setting.
Shaded cells indicate time of the blood collection after the bout of physical exercise.
BDI: before the drug injection; ADI: after the drug injection; HDLC: high-density lipoprotein cholesterol; AST: aspartate aminotransferase; ALT: alanine aminotransferase, ALKP: alkaline phospha-
tase; GGT: gamma-glutamyl transferase; TOTAL BILI: total bilirubin.
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aspartate aminotransferase concentrations after NSC631570 in-
troduction in an outpatient setting can be considered as an
outcome of the synergetic effect of the drug and physical ex-
ercise and could potentially affect the treatment efficacy of the
drug.Thus, consequences of treatment with NSC631570 against
the background of physical activity have to be monitored and
interpreted cautiously, taking into account the possible modu-
latory effect of physically active states on different metabolic
parameters and functions of immune system cells.
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